Arcellx Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
130
- Stock Symbol
-
ACLX
- Share Price
-
$71.35
- (As of Friday Closing)
Arcellx General Information
Description
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
Contact Information
Website
www.arcellx.comCorporate Office
- 25 West Watkins Mill Road
- Suite A
- Gaithersburg, MD 20878
- United States
Corporate Office
- 25 West Watkins Mill Road
- Suite A
- Gaithersburg, MD 20878
- United States
Arcellx Timeline
Arcellx Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $71.35 | $70.37 | $30.88 - $75.10 | $3.84B | 53.8M | 453K | -$1.04 |
Arcellx Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 2,466,250 | 2,551,047 | 1,164,682 | |
| Revenue | 144,745 | 110,319 | 0 | 0 |
| EBITDA | (77,432) | (87,840) | (189,938) | (63,977) |
| Net Income | (53,892) | (70,690) | (188,679) | (64,969) |
| Total Assets | 734,306 | 825,132 | 313,817 | 128,782 |
| Total Debt | 74,291 | 97,625 | 88,131 | 0 |
Arcellx Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Arcellx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Arcellx Comparisons
Industry
Financing
Details
000000
000000
Arcellx Competitors (17)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cartesian Therapeutics | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 000000000 | 00000 |
| AbelZeta | Venture Capital-Backed | Rockville, MD | 000 | 00000 | 00000000000 | 00000 |
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | 000 | 00.000 | 00000000 | 00.000 |
| Senti Bio | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 000000000000 | 00000 |
| Sutro Biopharma | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
Arcellx Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Arcellx Patents
Arcellx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230250185-A1 | D-domain containing polypeptides and uses thereof | Active | 15-Nov-2021 | 00000000000 | |
| US-11827716-B2 | D-domain containing polypeptides and uses thereof | Active | 15-Nov-2021 | 00000000000 | 00 |
| AU-2022388811-A1 | D-domain containing polypeptides and uses thereof | Pending | 15-Nov-2021 | 00000000000 | |
| CA-3237239-A1 | D-domain containing polypeptides and uses thereof | Pending | 15-Nov-2021 | 00000000000 | |
| US-20240124605-A1 | D-domain containing polypeptides and uses thereof | Pending | 15-Nov-2021 | C07K16/2866 |
Arcellx Executive Team (15)
| Name | Title | Board Seat |
|---|---|---|
| Rami Elghandour | Chief Executive Officer & Chairman | |
| Michelle Gilson | Chief Financial Officer, Finance & Chief Accounting Officer, Accounting | |
| Michael Dombeck | Chief Operating Officer | |
| Narinder Singh | Chief Technology Officer | |
| Kate Aiken | Chief People Officer |
Arcellx Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Ali Behbahani MD | New Enterprise Associates | Board Member | 000 0000 |
| Ali Behbahani MD | Self | Board Member | 000 0000 |
| David Lubner | Self | Board Member | 000 0000 |
| Derek Yoon | AJU IB Investment | Board Member | 000 0000 |
| Jill Carroll | SR One Capital Management | Board Member | 000 0000 |
Arcellx Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Arcellx Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Arcellx ESG
Risk Overview
Risk Rating
Updated November, 30, 2022
26.91 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Biotechnology
Subindustry
00 of 404
Rank
Percentile
Arcellx FAQs
-
When was Arcellx founded?
Arcellx was founded in 2014.
-
Who is the founder of Arcellx?
David Hilbert Ph.D is the founder of Arcellx.
-
Who is the CEO of Arcellx?
Rami Elghandour is the CEO of Arcellx.
-
Where is Arcellx headquartered?
Arcellx is headquartered in Gaithersburg, MD.
-
What is the size of Arcellx?
Arcellx has 130 total employees.
-
What industry is Arcellx in?
Arcellx’s primary industry is Drug Discovery.
-
Is Arcellx a private or public company?
Arcellx is a Public company.
-
What is Arcellx’s stock symbol?
The ticker symbol for Arcellx is ACLX.
-
What is the current stock price of Arcellx?
As of 06-Sep-2024 the stock price of Arcellx is $71.35.
-
What is the current market cap of Arcellx?
The current market capitalization of Arcellx is $3.84B.
-
What is Arcellx’s current revenue?
The trailing twelve month revenue for Arcellx is $145M.
-
Who are Arcellx’s competitors?
Cartesian Therapeutics, AbelZeta, Allogene Therapeutics, Senti Bio, and Sutro Biopharma are some of the 17 competitors of Arcellx.
-
What is Arcellx’s annual earnings per share (EPS)?
Arcellx’s EPS for 12 months was -$1.04.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
